Magazine

Quality reporting has changed the stakes in all aspects of healthcare. We’ve come to rely on metrics to guide decision-making across the clinical and business enterprises because the data never lie. Or do they?

Accelerating the integration of digital healthcare tools in a responsible, clinically meaningful way is the primary focus of the American College of Cardiology’s (ACC) innovation agenda, according to John Rumsfeld, MD, PhD, who spoke at the 2018 Cardiovascular Summit in February.

Physicians and patients have long awaited the next step beyond catheter ablation for ventricular tachycardia (VT). Could noninvasive stereotactic body radiation be that
breakthrough?

With 45 percent of today’s cardiologists older than 56 and a quarter of nurses who are planning to retire aiming to do so within the year, experts predict a workforce shortage will hit when the baby boomers are increasingly in need of care.

The entry of new players and dozens of potentially disruptive mergers and acquisitions are pushing healthcare in nontraditional directions, yielding opportunities for cardiologists to help shape the transformation.

When the prices of two generic medications skyrocketed, health systems worked to rein in costs while ensuring patients continued to receive high-quality care.

Sometimes the planets align. This time, it’s to the advantage of patients at risk of in-hospital cardiac arrest. While a study recently confirmed cardiac arrest survival rates fall significantly on nights and weekends, another study shows that a wearable defibrillator can help patients 24/7.

The cardiology community is paying close attention to developments related to transcatheter mitral valve replacement (TMVR) for mitral regurgitation. Although TMVR is in its infancy, one big question on everyone’s minds is whether its impact will be on the same scale as transcatheter aortic valve replacement (TAVR).

Could the ORBITA trial’s enduring value be in prompting the cardiology community to rethink how it diagnoses, treats and even defines angina?

A small but growing number of survivorship clinics for congenital heart disease (CHD) patients are popping up in healthcare systems across the country, but some cardiologists wonder if the model is sustainable.

Known for its conservative and what many call risk-averse nature, the Food and Drug Administration (FDA) seems to be headed in a bold and ambitious direction under Commissioner Scott Gottlieb, MD. What will his leadership mean for cardiology?

By targeting inefficiencies, a quality improvement program led to gains of approximately five or more hours per day in cath lab time. The approach could work as a model for other practices.

Select an Issues